Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions.
about
Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and childrenAddition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthmaAddition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and childrenAddition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adultsCurrent trends in the treatment of asthma: focus on the simultaneous administration of salmeterol/fluticasone.Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease.Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease.Tolerability profiles of leukotriene receptor antagonists and long-acting beta2-adrenoceptor agonists in combination with inhaled corticosteroids for treatment of asthma: a review.Batch-to-batch pharmacokinetic variability confounds current bioequivalence regulations: A dry powder inhaler randomized clinical trialBetween-Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial.Salmeterol/fluticasone propionate combination in the treatment of COPD.Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers.Fluticasone uptake across Calu-3 cells is mediated by salmeterol when deposited as a combination powder inhaler.The long-acting β2 -adrenoceptor agonist, indacaterol, enhances glucocorticoid receptor-mediated transcription in human airway epithelial cells in a gene- and agonist-dependent mannerPro- and anti-inflammatory factors cooperate to control hyaluronan synthesis in lung fibroblasts.Are salmeterol's beneficial effects on corticosteroid action in the airways executed at the epithelial barrier?Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults.Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects.The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol.
P2860
Q24235303-FEC86C6C-F128-4735-8D27-6A8707A67CC6Q24235964-A61F8083-4809-459C-98E9-07F39635F855Q24240464-2B3A849C-E84F-4935-8128-329E20859B49Q24245719-D2AFC0E3-CCA6-447B-A074-B19277A18741Q34620194-3A329FE7-2226-4655-9FCB-8D5C88AE2BD2Q35627818-F07DDCB9-D496-47AC-AE30-0AE5B0AEDAAEQ35841604-81957184-A205-4A47-B6C9-370F828E4107Q36892408-78FD4ED1-A11D-4B07-99FA-E8AEDCFA9AD7Q37404474-C294F204-FE86-4842-8301-41A6830172EDQ37664466-42CE9B6A-1317-45B2-A2CC-2A3248B1D4F4Q37754942-E06C5BDC-0553-4190-BDE1-EBBC76B1F772Q38856871-956895C3-DB95-4033-8C86-59793A003B99Q39135769-46EE8D5A-A43C-4B1C-9E8B-7D3D8106D2E3Q39960078-082E30F7-2241-4548-9BE9-9B607A084A34Q44756854-CD0B2720-5480-4BBF-B3EC-1CF86E7D7824Q45990688-51CE60DA-7589-4C67-B806-41E0F6F7D940Q46486322-6BDED0EA-48E7-43E6-A5B1-EE67359F706FQ51246235-FCBBA3E0-C917-4394-97A7-307C05519BB8Q51671642-F541B4EF-641F-4B5B-BEBC-543F3627C2AF
P2860
Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Salmeterol and fluticasone pro ...... pharmacokinetic interactions.
@ast
Salmeterol and fluticasone pro ...... pharmacokinetic interactions.
@en
type
label
Salmeterol and fluticasone pro ...... pharmacokinetic interactions.
@ast
Salmeterol and fluticasone pro ...... pharmacokinetic interactions.
@en
prefLabel
Salmeterol and fluticasone pro ...... pharmacokinetic interactions.
@ast
Salmeterol and fluticasone pro ...... pharmacokinetic interactions.
@en
P2093
P356
P1476
Salmeterol and fluticasone pro ...... pharmacokinetic interactions.
@en
P2093
Squassante L
Ventresca GP
P2888
P304
P356
10.1007/S002280000233
P577
2001-01-01T00:00:00Z
P5875
P6179
1050750124